Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved
Executive Summary
FDA is declining to rule out the possibility that the Sec. 505(b)(2) process could be used to allow expedited approval of follow-on biologic projects
You may also be interested in...
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer
FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains